Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 23, No. 3, 2010
Issue release date: March 2010
Section title: Original Paper
Free Access
Skin Pharmacol Physiol 2010;23:139–151

Identification of Novel in vitro Test Systems for the Determination of Glucocorticoid Receptor Ligand-Induced Skin Atrophy

Schoepe S.a, b · Schäcke H.a · Bernd A.c · Zöller N.c · Asadullah K.b, d
aCommon Mechanism Research Berlin and bTarget Discovery, Global Drug Discovery, Bayer Schering Pharma AG, Berlin, and cDepartment of Dermatology and Venerology, J.W. Goethe University, Frankfurt/Main, and dGerman Skin Research Center, Berlin, Germany
email Corresponding Author

Prof. Dr. med. Khusru Asadullah

Target Discovery, Bayer Schering Pharma AG

DE–13342 Berlin (Germany)

Tel. +49 30 468 14853, Fax +49 30 468 192 374

E-Mail khusru.asadullah@bayerhealthcare.com


  1. Sterry W, Asadullah K: Topical glucocorticoid therapy in dermatology. Ernst Schering Res Found Workshop 2002;40:39–54.
  2. Niedner R: Glukokortikosteroide in der Dermatologie: Kontrollierter Einsatz erforderlich. Dtsch Ärztebl 1996;93:A2868–A2872.
  3. Luger T, Loske KD, Elsner P, Kapp A, Kerscher M, Korting HC, Krutmann J, Nickner R, Röcken M, Ruzicka T, Schwarz T: Topische Dermatotherapie mit Glukokortikoiden – Therapeutischer Index. J Dtsch Dermatol Ges 2004;2:629–634.
  4. Korting HC, Unholzer A, Schafer-Korting M, Tausch I, Gassmueller J, Nietsch KH: Different skin thinning potential of equipotent medium-strength glucocorticoids. Skin Pharmacol Appl Skin Physiol 2002;15:85–91.
  5. Kimura T, Doi K: Dorsal skin reactions of hairless dogs to topical treatment with corticosteroids. Toxicol Pathol 1999;27:528–535.
  6. Booth BA, Tan EM, Oikarinen A, Uitto J: Steroid-induced dermal atrophy: effects of glucocorticosteroids on collagen metabolism in human skin fibroblast cultures. Int J Dermatol 1982;21:333–337.
  7. Mills CM, Marks R: Side effects of topical glucocorticoids. Curr Probl Dermatol 1993;21:122–131.
  8. Kolbe L, Kligman AM, Schreiner V, Stoudemayer T: Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin. Skin Res Technol 2001;7:73–77.
  9. Kao JS, Fluhr JW, Man MQ, Fowler AJ, Hachem JP, Crumrine D, Ahn SK, Brown BE, Elias PM, Feingold KR: Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol 2003;120:456–464.
  10. Sheu HM, Yu HS, Sheen TC: Histochemical and ultrastructural studies on cutaneous side effects due to topical corticosteroids. 1. Changes in epidermis. Derm Sinica 1989;7:143–153.
  11. Saarni H, Hopsu-Havu VK: The decrease of hyaluronate synthesis by anti-inflammatory steroids in vitro. Br J Dermatol 1978;98:445–449.
  12. Lehmann P, Zheng P, Lavker RM, Kligman AM: Corticosteroid atrophy in human skin. A study by light, scanning, and transmission electron microscopy. J Invest Dermatol 1983;81:169–176.
  13. Cutroneo KR, Rokowski R, Counts DF: Glucocorticoids and collagen synthesis: comparison of in vivo and cell culture studies. Coll Relat Res 1981;1:557–568.
  14. Nuutinen P, Autio P, Hurskainen T, Oikarinen A: Glucocorticoid action on skin collagen: overview on clinical significance and consequences. J Eur Acad Dermatol Venereol 2001;15:361–362.
  15. Schoepe S, Schäcke H, May E, Asadullah K: Glucocorticoid therapy-induced skin atrophy. Exp Dermatol 2006;15:406–420.
  16. Schäcke H, Docke WD, Asadullah K: Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96:23–43.
  17. Mirshahpanah P, Döcke WD, Merbold U, Asadullah K, Röse L, Schäcke H, Zollner TM: Superior nuclear receptor selectivity and therapeutic index of methylprednisolone aceponate versus mometasone furoate. Exp Dermatol 2007;16:753–761.
  18. Schäcke H, Schottelius A, Döcke WD, Strehlke P, Jaroch S, Schmees N, Rehwinkel H, Hennekes H, Asadullah K: Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA 2004;101:227–232.
  19. Wach F, Bosserhoff A, Kurzidym U, Nowok K, Landthaler M, Hein R: Effects of mometasone furoate on human keratinocytes and fibroblasts in vitro. Skin Pharmacol Appl Skin Physiol 1998;11:43–51.
  20. Ponec M, De Haas C, Bachra BN, Polano MK: Effects of glucocorticosteroids on cultured human skin fibroblasts. 3. Transient inhibition of cell proliferation in the early growth stages and reduced susceptibility in later growth stages. Arch Dermatol Res 1979;265:219–227.
  21. Schäcke H, Berger M, Rehwinkel H, Asadullah K: Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol 2007;275:109–117.
  22. Kurzen H, Henrich C, Booken D, Poenitz N, Gratchev A, Klemke CD, Engstner M, Goerdt S, Maas-Szabowski N: Functional characterization of the epidermal cholinergic system in vitro. J Invest Dermatol 2006;126:2458–2472.
  23. Mewes KR, Raus M, Bernd A, Zöller NN, Sattler A, Graf R: Elastin expression in a newly developed full-thickness skin equivalent. Skin Pharmacol Physiol 2007;20:85–95.
  24. Schottelius AJ, Zugel U, Docke WD, Zollner TM, Rose L, Mengel A, Buchmann B, Becker A, Grutz G, Naundorf S, Friedrich A, Gaestel M, Asadullah K: The role of mitogen-activated protein kinase-activated protein kinase 2 in the p38/TNF-alpha pathway of systemic and cutaneous inflammation. J Invest Dermatol 2009, E-pub ahead of print.
  25. Li YY, Bao M, Meurer J, Skuballa W, Bauman JG, Doecke WD, Zollner TM: The identification of a small molecule inhibitor that specifically reduces T cell-mediated adaptive but not LPS-mediated innate immunity by T cell membrane-monocyte contact bioassay. Immunol Lett 2008;117:114–118.
  26. Zöller NN, Kippenberger S, Thaci D, Mewes K, Spiegel M, Sattler A, Schultz M, Bereiter-Hahn J, Kaufmann R, Bernd A: Evaluation of beneficial and adverse effects of glucocorticoids on a newly developed full-thickness skin model. Toxicol In Vitro 2008;22:747–759.
  27. Zerbe GO: On Fieller’s theorem and the general linear model. The Am Stat 1978;32:103–105.
    External Resources
  28. Dixon WJ: Processing data for outliers. Biometrics 1953;9:74–89.
    External Resources
  29. Wiedersberg S, Leopold CS, Guy RH: Bioavailability and bioequivalence of topical glucocorticoids. Eur J Pharm Biopharm 2008;68:453–466.
  30. Commandeur S, de Gruijl FR, Willemze R, Tensen CP, El Ghalbzouri A: An in vitro three-dimensional model of primary human cutaneous squamous cell carcinoma. Exp Dermatol 2009;18:849–856.